. 2019 Jun 5;8(6):805. doi: 10.3390/jcm8060805

Table 2.

Concentrations of plasma omentin-1, NGAL and CTRP3 in control subjects and obese patients with type 2 diabetes mellitus.

Parameters	Control Subjects	Obese Patients with Type 2 Diabetes Mellitus
Parameters	Control Subjects	Before the Implementation of Insulin Therapy	After a 6-Month Insulin Treatment
Omentin-1 (ng/mL)	464.41 ± 214.92	516.44 ± 209.54	576.88 ± 174.31 ^a,d
NGAL (ng/mL)	36.98 ± 14.76	54.37 ± 23.24 ^b	66.51 ± 25.76 ^{c, e}
CTRP3 (ng/mL)	543.71 ± 69.86	531.98 ± 60.1	479.06 ± 72.95 ^{b, f}

Values given as mean ± SD; NGAL, neutrophil gelatinase-associated lipocalin; CTR3, C1q/TNF-related protein-3; ^a p<0.05, compared to controls; ^b p <0.01, compared to controls; ^c p <0.0001, compared to controls; ^d p <0.05, compared to diabetic patients before insulin therapy; ^e p <0.01, compared to diabetic patients before insulin therapy; ^f p <0.0001, compared to diabetic patients before insulin therapy.